US equities |
NVDA $186.64 ▲+2.78% MU $690.00 ▲+5.12% AMD $449.04 ▲+11.04% SPCX $134.27 ▲+8.62% AAPL $342.37 ▼-0.52% SNDK $835.06 ▲+3.55% MSFT $530.61 ▼-0.99% TSLA $358.22 ▲+4.23%
FinancialContent

Dynavax Technologies Corporation - Common Stock (NQ:DVAX)

15.50 UNCHANGED
Last Price Updated: 4:00 PM EST, Feb 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Dynavax Technologies Corporation - Common Stock

News headline image
Halper Sadeh LLC Encourages DVAX, FONR, DBRG, ONTF Shareholders to Contact the Firm to Discuss Their Rights
Shareholders should contact the firm as there may be limited time to enforce your rights 
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
CORRECTING and REPLACING Dynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies Corporation - DVAX
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
DVAX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Dynavax Technologies Corporation is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
Deep Track Capital Sends Letter to Dynavax Technologies Shareholders Offering Final Perspectives on Why Change is Needed in the Boardroom
From Deep Track Capital, LP
Via Business Wire
News headline image
Glass Lewis Recommends Shareholders Support Deep Track’s Case for Board Change at Dynavax Technologies
From Deep Track Capital, LP
Via Business Wire
News headline image
Deep Track Capital Comments on ISS Recommendation
From Deep Track Capital, LP
Via Business Wire
News headline image
Deep Track Capital Issues Letter to Fellow Dynavax Technologies Shareholders Detailing Critical Issues in Advance of Annual Meeting
From Deep Track Capital, LP
Via Business Wire
News headline image
Deep Track Capital Releases Investor Presentation on Dynavax Technologies
From Deep Track Capital, LP
Via Business Wire
News headline image
Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow Shareholders
From Deep Track Capital, LP
Via Business Wire
News headline image
Deep Track Capital Comments on Dynavax Technologies’ Rejection of Most Recent Settlement Offer
From Deep Track Capital, LP
Via Business Wire
News headline image
Deep Track Capital Sends Letter to Dynavax Technologies’ Board of Directors
From Deep Track Capital, LP
Via Business Wire
News headline image
Deep Track Capital Nominates Four Highly Qualified Candidates for Election to Dynavax Technologies’ Board of Directors at 2025 Annual Meeting
From Deep Track Capital, LP
Via Business Wire
News headline image
Glancy Prongay & Murray LLP Announces Investigation of Dynavax Technologies Corporation (DVAX)
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
Lantheus Appoints Julie Eastland as New Board Member
From Lantheus Holdings, Inc.
Via GlobeNewswire
News headline image
Clover Provides Updates on COVID-19 Vaccine Commercial Launch and Strategic Priorities in 2023
From Clover Biopharmaceuticals
Via GlobeNewswire
News headline image
Clover’s Vaccine Candidate Reduced Household Transmission of SARS-CoV-2 in Study Published in Clinical Infectious Diseases
From Clover Biopharmaceuticals
Via GlobeNewswire
News headline image
Clover Provides Update on 2022 Corporate Milestones
From Clover Biopharmaceuticals
Via GlobeNewswire
Global Antibiotic Resistance Market to Hit US$16.5 Billion By 2030
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 21, 2022 – Resistance to antibiotics is a growing concern. About 750,000 people die each year worldwide from... 
Via FinancialNewsMedia
Scientific Reports Revealing Early Promise for Universal Coronavirus Vaccine
Palm Beach, FL – October 20, 2021 – FinancialNewsMedia.com News Commentary – Recently, scientific reports have shown that a universal coronavirus vaccine that protects against COVID-19 causing... 
Via FinancialNewsMedia
As the Virus Continues, the Global Covid-19 Vaccine Market Expected to Reach $25 Billion By 2024
Via FinancialNewsMedia